This study focuses on individuals who have inoperable, early stage non-small cell lung cancer. The purpose of the study is to compare the usual treatment alone to using an immunotherapy drug called atezolizumab plus the usual treatment. The usual approach for patients who are not in a study is treatment with radiation alone. Researchers aim to determine whether patients’ lives can be extended by adding the immunotherapy drug atezolizumab to the usual radiation treatment. Participants will be randomly assigned to 1 of 2 groups. The first group will receive atezolizumab plus the usual radiation treatment, and the second group will receive the usual radiation treatment. The use of atezolizumab in this study is investigational.
What is the full name of this clinical trial?
S1914: A Randomized Phase III Trial of Induction/Consolidation Atezolizumab + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
Behrooz Hakimian, David Hoffman, Jeremy Lorber, Karen Reckamp, Katelyn Atkins, Kevin Scher, Ronald Natale, Sepehr Rokhsar, Sukhmani Padda